The investment company H2 Invest, a part of H2 Global Group, is shifting its focus from hydrogen mobility and energy to the promising fields of MedTech and HealthTech. Hydrogen technologies are finding faster practical applications in these sectors, offering more stable investment opportunities. "Hydrogen in medicine is not just a vision of the future, but a reality that is gradually gaining recognition among doctors and researchers," said Martin Frais, CEO of H2 Invest.
Ongoing projects in energy and mobility
H2 Invest continues to develop projects in the energy and mobility sectors. In energy, the company has completed a project for household use of surplus solar energy, which is converted into hydrogen via an electrolyzer. This hydrogen can then be stored and used when solar power is unavailable. The system allows households to better manage their energy consumption and achieve greater energy independence.
In the field of micromobility, H2 Global Group has developed the first hydrogen-powered bicycle, H2 Bike, for which it holds a utility model patent. The company is currently considering whether to sell the prototype or further develop and bring it to market. However, the absence of clear regulatory frameworks for hydrogen technologies at the European Union level remains a challenge, slowing down the broader adoption of these innovations.
Challenges in Hydrogen Technology Regulation
While the European Union has set goals for renewable hydrogen production and imports within its hydrogen strategy and REPowerEU plan, clear regulatory frameworks for its use in sectors such as micromobility are still lacking. This absence of unified rules creates uncertainty for manufacturers and investors, potentially hindering innovation and commercialization. According to the Czech Hydrogen Technology Platform (HYTEP), the current European regulations for renewable hydrogen production are too strict and complicate the sector’s growth in the Czech Republic.
"We currently face certain regulatory and subsidy challenges that hinder a quick return on investment," said Martin Frais, CEO of H2 Invest. "Without a clear legislative framework, the investment environment in hydrogen technologies remains uncertain. Regulations are constantly evolving, but their slow implementation delays the mass adoption of innovations. Nevertheless, we believe in the long-term potential of hydrogen and continue to work on projects that will be ready for future market conditions.”
Hydrogen in Healthcare: H2 Invest Bets on MedTech Innovation
Research confirms that molecular hydrogen has powerful antioxidant, anti-inflammatory, and neuroprotective properties, paving the way for its broader medical applications.
"Our goal is to establish hydrogen as a recognized medicinal gas and integrate it into standard treatment protocols," said Viktória Procházková, CEO of H2 Global Group. "Hydrogen therapy could revolutionize healthcare, supported by thousands of scientific studies confirming its effectiveness."
Hydrogen has the unique ability to penetrate all body cells, including the blood-brain barrier, making it an exceptional therapeutic agent. Due to its natural biological compatibility, it is completely free of side effects, further increasing its potential.
An Investment Opportunity with Long-Term Potential
H2 Invest sees huge growth potential in the MedTech and HealthTech sectors. “Hydrogen in medicine is not just a vision of the future; it is a reality that is gradually gaining recognition among doctors and researchers. H2 Group is actively building a sector with immense growth potential, whose boundaries are constantly expanding. That is why this is an investment with long-term prospects and high stability potential,” adds Martin Frais.
With this move, H2 Invest confirms its flexibility and ability to adapt to current market conditions, while continuing its existing projects in energy and mobility. The company remains committed to delivering innovative solutions across various sectors, with a strong emphasis on sustainability and technological advancement.
Do You Want to Be Part of the Future of Medicine?
Only until the end of March, you can invest from just CZK 50,000! Earn a fixed annual interest rate of 10%, plus a bonus interest of 3% in the first year, paid within 30 days of your investment! Learn more at www.H2Invest.cz.
